Gibson Oncology, LLC filed a Form D with the Securities and Exchange Commission on 2025-07-21.
Gibson Oncology, LLC filed a Form D notice of an exempt securities offering with the SEC on July 21, 2025. The filing reports $250K sold. Its industry group is Biotechnology. It names Randall Riggs (Executive Officer, Director), Theodore Solomon (Executive Officer, Director), Elizabeth Rogers (Executive Officer, Director) (SEC Form D, July 21, 2025).
Is this your company?
Sell to companies like Gibson Oncology, LLC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-07-21 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Gibson Oncology, LLC.
Free to see. No signup.
More on the people and the money behind Gibson Oncology, LLC, from the filings we hold.
Biotechnology raises by companies based in Florida, filed in July 2025, largest first.
Get an email when Gibson Oncology, LLC files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Gibson Oncology, LLC raises, hires or launches. No email unless you switch it on.
Watch Gibson Oncology, LLC →Get the full cited report on Gibson Oncology, LLC
What the filing shows about Gibson Oncology, LLC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Gibson Oncology, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Gibson Oncology, LLC's address as 7772 Fisher Island Drive, Miami, FL 33109.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Gibson Oncology, LLC is a registered filer with the SEC (CIK 2042777) and has filed since 2024-10-31. 2 filings are on record, the latest on 2025-07-21.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Gibson Oncology, LLC's Form D of 2025-07-21 names Randall Riggs, Theodore Solomon, Elizabeth Rogers and 4 more as its officers, directors or promoters.
Its new offerings report $4.05M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Randall Riggs is named as Executive Officer and Director on the Form D that Gibson Oncology, LLC filed with the SEC on 21 July 2025, one of 7 people that filing names.
Theodore Solomon is named as Executive Officer and Director on the Form D that Gibson Oncology, LLC filed with the SEC on 21 July 2025, one of 7 people that filing names.
Elizabeth Rogers is named as Executive Officer and Director on the Form D that Gibson Oncology, LLC filed with the SEC on 21 July 2025, one of 7 people that filing names.
Clifford Solomon is named as Executive Officer and Director on the Form D that Gibson Oncology, LLC filed with the SEC on 21 July 2025, one of 7 people that filing names.
Mark Rogers is named as Director on the Form D that Gibson Oncology, LLC filed with the SEC on 21 July 2025, one of 7 people that filing names.
Mark Cushman is named as Director on the Form D that Gibson Oncology, LLC filed with the SEC on 21 July 2025, one of 7 people that filing names.
Mark Baganz is named as Director on the Form D that Gibson Oncology, LLC filed with the SEC on 21 July 2025, one of 7 people that filing names.
7 people named on the filing — 4 holding an executive role and 3 as directors only.
Named as of the 2025-07-21 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Gibson Oncology, LLC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Gibson Oncology, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Gibson Oncology, LLC covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Gibson Oncology, LLCYou get an alert in MentionFox the next time this company shows up.
If you're behind Gibson Oncology, LLC: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Gibson Oncology, LLC. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Miami
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/gibson-oncology-llc-form-d-25000001